The Experts below are selected from a list of 21903 Experts worldwide ranked by ideXlab platform

Imad A. Alhaddad - One of the best experts on this subject based on the ideXlab platform.

Kenneth E. Otah - One of the best experts on this subject based on the ideXlab platform.

Thomas Zeller - One of the best experts on this subject based on the ideXlab platform.

  • drug coated balloon versus standard balloon for superficial femoral artery in Stent Restenosis the randomized femoral artery in Stent Restenosis fair trial
    Circulation, 2015
    Co-Authors: Hans Krankenberg, Thilo Tubler, Maja Ingwersen, Michael Schluter, Dierk Scheinert, Erwin Blessing, Sebastian Sixt, Arne Kieback, Ulrich Beschorner, Thomas Zeller
    Abstract:

    Background—Drug-coated balloon angioplasty (DCBA) was shown to be superior to standard balloon angioplasty (POBA) in terms of Restenosis prevention for de novo superficial femoral artery disease. For in-Stent Restenosis, the benefit of DCBA over POBA remains uncertain. Methods and Results—One hundred nineteen patients with superficial femoral artery in-Stent Restenosis and chronic limb ischemia were recruited over 34 months at 5 German clinical sites and prospectively randomized to either DCBA (n=62) or POBA (n=57). Mean lesion length was 82.2±68.4 mm. Thirty-four (28.6%) lesions were totally occluded; 30 (25.2%) were moderately or heavily calcified. Clinical and duplex ultrasound follow-up was conducted at 6 and 12 months. The primary end point of recurrent in-Stent Restenosis assessed by ultrasound at 6 months was 15.4% (8 of 52) in the DCBA and 44.7% (21 of 47) in the POBA group (P=0.002). Freedom from target lesion revascularization was 96.4% versus 81.0% (P=0.0117) at 6 months and 90.8% versus 52.6% ...

Ron Waksman - One of the best experts on this subject based on the ideXlab platform.

  • In-Stent Restenosis: A Second Chance to Get It Right
    Journal of the American College of Cardiology, 2020
    Co-Authors: Evan Shlofmitz, Nauman Khalid, Ron Waksman
    Abstract:

    The DAEDALUS (Difference in Antirestenotic Effectiveness of Drug-Eluting Stent and Drug-Coated Balloon Angioplasty for the Occurrence of Coronary In-Stent Restenosis) investigators ([1][1]) conducted an important study demonstrating the challenge of in-Stent Restenosis (ISR) and the poor outcomes

  • In-Stent Restenosis of drug-eluting Stents
    Future cardiology, 2013
    Co-Authors: Sa'ar Minha, Augusto D Pichard, Ron Waksman
    Abstract:

    Drug-eluting Stents (DES) have emerged as an improved alternative to bare-metal Stents by demonstrating reduced rates of Restenosis and target lesion revascularization. This emergence has led to the unrestricted use of DES for various indications and lesions, and subsequently revealed DES in-Stent Restenosis as a novel interventional therapeutic dilemma. Recent insights regarding the patho-physiological processes and therapeutic alternatives have added to the accumulated knowledge regarding the appropriate approach to this phenomenon. This review aims to detail the mechanism and clinical presentation of, and therapeutic strategies for, the treatment of DES in in-Stent Restenosis.

  • Clinical trials of intracoronary gamma radiation therapy for in-Stent Restenosis.
    The Journal of invasive cardiology, 2002
    Co-Authors: Dong-hun Cha, Andrew E. Ajani, Edouard Cheneau, Ron Waksman
    Abstract:

    The only gamma emitter used in clinical trials for in-Stent Restenosis is 192Iridium (192Ir). The efficacy of intracoronary gamma radiation therapy in reducing clinical and angiographic Restenosis in patients with in-Stent Restenosis has been established. This review is intended to give an overview of the clinical trials utilizing gamma vascular brachytherapy in patients with in-Stent Restenosis and give insight into the future of intracoronary radiation therapy.

  • Treatment of in-Stent Restenosis.
    Seminars in interventional cardiology : SIIC, 1998
    Co-Authors: G.s. Mintz, Ron Waksman, Lowell F Satler, Augusto D Pichard, Roxana Mehran, Kenneth M. Kent, Martin B. Leon
    Abstract:

    Although in-Stent Restenosis is the result of neointimal hyperplasia, mechanical problems (e.g. Stent underexpansion) that occurred during implantation may result in Restenosis at follow-up. The treatment of in-Stent Restenosis, begins with identification of these occult mechanical problems. Thereafter, in-Stent Restenosis can be treated with PTCA, atheroablation, or additional Stent implantation; it is nuclear which technique is superior. Not all in-Stent Restenosis lesions have a similar risk of recurrence. Recurrence appears to depend on several markers of biologic activity: focal vs diffuse in-Stent Restenosis, the first episode vs recurrent in-Stent Restenosis, and early vs late recurrence. Vascular brachytherapy has emerged as the most promising way to treat high-risk lesion subsets.

Wang Lei - One of the best experts on this subject based on the ideXlab platform.

  • The Renin-angiotensin System and In-Stent Restenosis
    Advances in Cardiovascular Diseases, 2006
    Co-Authors: Wang Lei
    Abstract:

    The renin-angiotensin system (RAS) can regulate smooth muscle cell (SMC) proliferation and migration, and play an important role in in-Stent Restenosis. There are contradictory effects of preventing in-Stent Restenosis to inhibit RAS by angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers. This review discusses the pathophysiology of in-Stent Restenosis, the role of the RAS in in-Stent Restenosis, and the possible role of RAS intervention in the prevention of in-Stent Restenosis.